Jonathan Young Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of Akero Therapeutics stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $53.81, for a total transaction of $538,100.00. Following the completion of the sale, the chief operating officer now owns 251,147 shares of the company’s stock, valued at $13,514,220.07. This represents a 3.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jonathan Young also recently made the following trade(s):

• On Thursday, January 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00.
• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total transaction of $77,067.37.
• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.13, for a total transaction of $321,300.00.

Akero Therapeutics Price Performance

AKRO opened at $54.21 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of -14.46 and a beta of -0.11. The firm’s fifty day moving average price is $32.60 and its two-hundred day moving average price is $29.85. Akero Therapeutics, Inc. has a 1 year low of $17.84 and a 1 year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). As a group, analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AKRO has been the subject of several research analyst reports. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. HC Wainwright lifted their price target on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, January 27th. UBS Group lifted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Morgan Stanley lifted their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Finally, Citigroup lifted their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akero Therapeutics has a consensus rating of “Buy” and an average price target of $75.86.

Hedge Funds Weigh In On Akero Therapeutics

A number of hedge funds have recently bought and sold shares of the company. AlphaQuest LLC boosted its holdings in shares of Akero Therapeutics by 32,588.0% in the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company’s stock worth $227,000 after buying an additional 8,147 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in shares of Akero Therapeutics in the 4th quarter worth about $320,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Akero Therapeutics by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company’s stock worth $15,042,000 after buying an additional 8,096 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Akero Therapeutics by 5.0% in the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company’s stock worth $584,000 after buying an additional 1,000 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Akero Therapeutics by 1.3% in the 4th quarter. Rhumbline Advisers now owns 105,686 shares of the company’s stock worth $2,940,000 after buying an additional 1,310 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.